Thenalidine
Identification
- Name
- Thenalidine
- Accession Number
- DB04826
- Description
Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Thenalidine (DB04826)
- Weight
- Average: 286.435
Monoisotopic: 286.150369404 - Chemical Formula
- C17H22N2S
- Synonyms
- 1-Methyl-4-amino-N-phenyl-N-(2-thenyl)piperidine
- 1-Methyl-4-N-2-thenylanilinopiperidine
- Tenalidina
- Thenalidine
- Thenalidinum
- Thenophenopiperidine
- External IDs
- AS 716
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
Pathway Category Thenalidine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataDroxidopa The therapeutic efficacy of Droxidopa can be increased when used in combination with Thenalidine. Ephedrine The therapeutic efficacy of Ephedrine can be increased when used in combination with Thenalidine. Epinephrine The therapeutic efficacy of Epinephrine can be increased when used in combination with Thenalidine. Levonordefrin The therapeutic efficacy of Levonordefrin can be increased when used in combination with Thenalidine. Norepinephrine The therapeutic efficacy of Norepinephrine can be increased when used in combination with Thenalidine. Protokylol The therapeutic efficacy of Protokylol can be increased when used in combination with Thenalidine. Racepinephrine The therapeutic efficacy of Racepinephrine can be increased when used in combination with Thenalidine. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- International/Other Brands
- Sanbosten / Sandostene
Categories
- ATC Codes
- R06AX03 — Thenalidine
- R06AX — Other antihistamines for systemic use
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
- R06AX — Other antihistamines for systemic use
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- Dialkylarylamines
- Alternative Parents
- Aniline and substituted anilines / Aralkylamines / Aminopiperidines / Thiophenes / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- 4-aminopiperidine / Aniline or substituted anilines / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Dialkylarylamine / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 6U94N2D00F
- CAS number
- 86-12-4
- InChI Key
- KLOHYVOVXOUKQI-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H22N2S/c1-18-11-9-16(10-12-18)19(14-17-8-5-13-20-17)15-6-3-2-4-7-15/h2-8,13,16H,9-12,14H2,1H3
- IUPAC Name
- 1-methyl-N-phenyl-N-[(thiophen-2-yl)methyl]piperidin-4-amine
- SMILES
- CN1CCC(CC1)N(CC1=CC=CS1)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 27901
- PubChem Substance
- 46504731
- ChemSpider
- 25957
- ChEBI
- 135187
- ChEMBL
- CHEMBL2105458
- ZINC
- ZINC000000002146
- Wikipedia
- Thenalidine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 96 °C PhysProp boiling point (°C) 159 °C at 2.00E-02 mm Hg PhysProp - Predicted Properties
Property Value Source Water Solubility 0.0883 mg/mL ALOGPS logP 4.47 ALOGPS logP 3.75 ChemAxon logS -3.5 ALOGPS pKa (Strongest Basic) 8.69 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 6.48 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 87.44 m3·mol-1 ChemAxon Polarizability 32.89 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9679 Blood Brain Barrier + 0.9862 Caco-2 permeable + 0.6921 P-glycoprotein substrate Substrate 0.6784 P-glycoprotein inhibitor I Non-inhibitor 0.7908 P-glycoprotein inhibitor II Non-inhibitor 0.542 Renal organic cation transporter Inhibitor 0.7914 CYP450 2C9 substrate Non-substrate 0.7078 CYP450 2D6 substrate Substrate 0.5511 CYP450 3A4 substrate Non-substrate 0.5881 CYP450 1A2 substrate Inhibitor 0.6618 CYP450 2C9 inhibitor Non-inhibitor 0.8589 CYP450 2D6 inhibitor Inhibitor 0.8765 CYP450 2C19 inhibitor Non-inhibitor 0.7584 CYP450 3A4 inhibitor Non-inhibitor 0.9589 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5834 Ames test Non AMES toxic 0.8307 Carcinogenicity Non-carcinogens 0.9578 Biodegradation Not ready biodegradable 0.9913 Rat acute toxicity 2.4636 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.771 hERG inhibition (predictor II) Inhibitor 0.6166
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on September 11, 2007 14:30 / Updated on June 12, 2020 10:52
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates